Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 10/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26117247 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL30608416 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL1686982 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL1534272 | 0.86 | HTR2B (0.76) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL15423011 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL3993242 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL11925403 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL3993320 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL11050644 | 0.85 | HTR2B (0.74) | HTR2BHTR1DHTR7HTR3ARAB9A | |
| SCHEMBL11050648 | 0.84 | HTR2B (0.72) | HTR2BHTR1DHTR7HTR3ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2012051502-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | TACR2, TACR3, TACR1 | HTR2B 58/4885HTR1D 154/4885HTR7 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.